Hugh Calkins



Hugh Calkins is the Nicholas J Fortuin professor of cardiology, professor of medicine, director of the Cardiac Arrhythmia Services, director of the Electrophysiology Laboratory, and the director of Johns Hopkins ARVD/C Program at Johns Hopkins University School of Medicine, Baltimore, USA. He is also chair of the Heart Rhythm 2012 Scientific Sessions Program Committee (9–12 May, Boston, USA) and the lead author of the updated Heart Rhythm Society/ European Heart Rhythm Association/European Cardiac Arrhythmia Society (HRS/EHRA/ECAS) consensus document on catheter and surgical ablation of atrial fibrillation. He talked to Cardiac Rhythm News about his career highlights, Heart Rhythm 2012, and the new consensus document.

Why did you decide to become a doctor and in particular, why did you choose to specialise in electrophysiology?

I decided to go into medicine when I was a teenager growing up in the small town of Hamburg, New York, which is a suburb of Buffalo. Both my parents are physicians. My father, a rheumatologist, was chief of Medicine at the University of Buffalo and my mother was a general physician at a psychiatric hospital in Gowanda, New York. I am the sixth of their nine children. Three of us (of the children) went into medicine.

When I started my cardiology fellowship at Johns Hopkins, I was initially interested in heart failure. However, during my first year of fellowship, I met Joe Levine who was an attending physician on the electrophysiology (EP) Service. He convinced me that EP was the most interesting field to pursue and took me under his wing. We designed several research studies, one of which resulted in me being the recipient of the North American Society of Pacing and Electrophysiology (NASPE) Young Investigator Award. It was this experience that helped fuel my interest in an academic career.

Who in your career has had the greatest influence on you and why?

I have been very fortunate to have worked with a long list of superstars in cardiology and electrophysiology. Some of these individuals include (ordered by institution and chronological date): Jeremy Ruskin, Warren Harthorne (Massachusetts General Hospital), Michel Mirowski, Myron Weissfeldt, Ken Baughman, David Kass, Tom Guarnieri, Jeff Brinker, Gordon Tomaselli, Ron Berger, Joe Levine (Johns Hopkins), Fred Morady, Alan Kadish (University of Michigan), Eric Prystowsky, Sonny Jackman, Frank Marcus, Al Waldo, Doug Zipes, and many others from the broader EP community. I recognise that this is a very long list. Any success I may have enjoyed did not happen in a vacuum. I was very fortunate and was provided outstanding opportunities.

It is very difficult to rank each of these individuals in terms of their influence on my career. But if I was forced to identify two individuals that I would want to especially acknowledge, it would be Joe Levine who convinced me to go into EP and helped foster my early research experience and Fred Morady. I spent two months as a visiting fellow at the University of Michigan in 1988. I was lucky enough to join their faculty in 1989.

During my first year on the faculty, I worked as a fellow in the EP lab under Fred Morady. Fred was a remarkable teacher and role model. Much of what I have learned about EP and about being a physician and an academic electrophysiologist, I learnt from Fred. He is a great teacher, a great electrophysiologist, and a great friend.

In your view, during your medical career, what has been the most important development in the management of heart rhythm disorders?

I would have to vote for radiofrequency catheter ablation. The field really began when I joined the faculty at the University of Michigan in 1989. You cannot imagine the excitement associated with performing our radiofrequency first ablation procedures for Wolff Parkinson White syndrome, atrioventricular nodal re-entry tachycardia and ventricular tachycardia. My second vote would be for the implantable defibrillator.

When I arrived at Johns Hopkins in 1986, implantable cardioverter defibrillators (which were referred to as AIDs at the time) were being implanted in the operating room by Levi Watkins on a regular basis. It was remarkable to see how nonthoracotomy lead systems revolutionised this therapy.

Your list of research activities is extensive with more than 400 published manuscripts. Which piece of research are you most proud of?

I am most proud of my research on two topics. The first is catheter ablation. As I mentioned above, I was on the scene when the field was in its infancy and I was provided with material to write clinically oriented manuscripts. These manuscripts, which I wrote with Fred Morady, helped to define the field of radiofrequency ablation. In 1991, I was the first author of a paper published in the NEJM, titled “Diagnosis and Cure of the Wolff Parkinson White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test” (N Engl J Med 1991; 324:1612–18). Fred Morady was the senior author.

This was a great moment. Since these early days, my interest in catheter ablation has continued. My research has focused on catheter ablation of all types of cardiac arrhythmias including atrial tachycardia, atrial flutter, and ventricular tachycardia. For the past decade, I have focused predominantly on catheter ablation of atrial fibrillation. The second body of research which I have been particularly proud of is my series of publications on arrhythmogenic right ventricular dysplasia (ARVD). I got interested in this disease 14 years ago and since then have had a wonderful time examining interesting questions concerning the diagnosis and management of ARVD. Our database now contains information on more than 1,000 patients.

At Boston AF, you reviewed the 2012 update of the 2007 HRS/EHRA/ECAS consensus document on atrial fibrillation ablation. Logistically, how did you ensure that all views of the writing committee members and societies involved were considered and that a consensus was reached?

Last year (2011), I had the opportunity to lead this joint effort by the HRS, EHRA, and ECAS. Karl-Heinz Kuck and Riccardo Cappato helped lead this effort with me. We used anonymous surveys to identify where there was and was not a consensus. The process began by having the 45 members of the writing group submit questions to be included in anonymous surveys of the group. All members of the writing group were responsible for answering each question and also to add comments. We then examined the responses to determine where there was and was not a consensus. We also included this information throughout our manuscript. In the section where we discuss sedation, for example, we included a sentence that approximately 50% of writing group members routinely perform atrial fibrillation ablation procedures under general anaesthesia.

You said that the most important change in the document is probably that there is now a class and level-of-evidence designation for each indication for ablation for atrial fibrillation. Why is this the most important change and why was it felt necessary to add it?

These changes reflect the fact that there is now a very large body of literature that has defined the outcomes of atrial fibrillation ablation.

Another important change is that the document now has updated recommendations on anticoagulation therapy. Of these updates on anticoagulation therapy, what do you think is the most important “take-home” message?

One of the most important is the acknowledgement that it is now very reasonable to perform an atrial fibrillation ablation procedure in a patient therapeutically anticoagulated with warfarin. Another important message is that a patient’s stroke risk profile, and not the perceived presence or absence of atrial fibrillation, should be used to guide decisions regarding long-term anticoagulation therapy following catheter ablation. This reflects the fact that atrial fibrillation recurrences are not uncommon following ablation, that recurrent atrial fibrillation may be asymptomatic, and that patients “pick up” stroke risk factors over time.

The new document also recommends that the CHA2DS2-VASc score is used to assess the risk of stroke in patients with atrial fibrillation. What are the additional benefits of this system compared with the CHADS2 system?

I am convinced that the CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack, vascular disease, age 65–74 years, sex category) score is superior to the CHADS2 scoring system. This reflects the fact that many patients who have a CHADS2 score of 1 remain at significant risk of a stroke. The CHA2DS2-VASc score helps divide these patients into those with a higher and those with a lower risk of stroke. This information can then be used to guide decisions about anticoagulation. I recognise that some in our field find that general cardiologists cannot even remember the CHADS2 scoring system and that it would be a mistake to teach them an even more complex system. I am more of an optimist in this regard.

The guidelines recommend areas of future research. In your opinion, what are the priorities for research?

Although atrial fibrillation ablation has come a long way, I do not think anyone in the field is content with the current efficacy of the procedures nor are they happy with the complication rate. So, research on new ablation techniques and technologies that will improve the outcomes of the procedure are needed. In addition, we need to learn more about the safety and efficacy of atrial fibrillation ablation in populations of patients not well represented in clinical trials. These patient populations include those long standing persistent atrial fibrillation, those with heart failure, the elderly, and so forth. We also need to know more about the impact of ablation on hard endpoints such as stroke risk and mortality.

What has been the impact of the 2007 document?

It had a very significant impact on our field. Not only did it define best practices for atrial fibrillation ablation as of 2007, it also made recommendations concerning training as well as the design of clinical trials. Most of the recommendations that were made by the writing group have subsequently been adopted worldwide.

At Boston AF, you also gave a talk about clinical trials in atrial fibrillation ablation. Which recent paper on atrial fibrillation has been the most interesting and which current studies are you most interested in seeing the results of?

There are a large number of ongoing trials that have been designed specifically to get a new technology approved by the FDA for use in atrial fibrillation ablation. I am very interested to see what the two trials of contact sensing ablation catheters will show. One of these studies has completed enrolment and the other is at the half-way point. We all hope that by directly measuring tissue contact, ablation safety and efficacy will improve. We will have to wait at least a year to find out the answer.

As chair of the scientific programme committee for Heart Rhythm 2012, in your view, what are the highlights of this year’s programme?

There will be many highlights of the meeting. Some of these are continued from prior meetings-such as the late breaking abstract sessions, the best technology abstract sessions, the AF Summit, and the Basic Science Forum-and other highlights are new. This year, for example, we have added a significant number of “how to” sessions. Although some of our colleagues come to learn about the latest breakthrough treatments, others come to improve their skills. It is for this reason we decided to include “how to” sessions throughout the meeting.

Another new feature this year are several board review sessions on Saturday morning that are designed specifically for those who will be taking the International Board of Heart Rhythm Examiners (IBHRE) Examination or the EP Board Examinations this year. The focus of the meeting this year is on “our patients”. We chose this to emphasise the fact that everything we do as heart rhythm professionals is aimed at ending death and suffering due to heart rhythm disorders.

You have mentored people throughout your career. What do you find most rewarding about mentoring people?

I very much enjoy training and mentoring the next generation of electrophysiologists and researchers in our field. Not only do the trainees I have worked with bring a lot of enthusiasm and hard work to bear on a particular problem, they also have great ideas. I very much enjoy watching their careers when they complete their training and go forth to start their own careers.

Outside of medicine, what are your interests?

Top on my list is my family. I have a wonderful wife Beth, and three children Emily, Daniel, and Eliza. I particularly enjoy sailing, skiing, travel, and playing tennis.


Fact File

Current professional appointments

2008–present Nicholas J Fortuin professor of Cardiology, Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, USA

2000–present Professor of Medicine, Department of Medicine, Division of Cardiology, The Johns Hopkins University School of Medicine, Baltimore, USA

2000–present Professor of Pediatrics, Department of Pediatrics, Division of Pediatric Cardiology, The Johns Hopkins University School of Medicine, Baltimore,USA

1995–present Director of the Tilt Diagnostic Lab, The Johns Hopkins University School of Medicine, Baltimore, USA

1992–present Director of the Arrhythmia Service, Clinical Electrophysiology Laboratory, and Arrhythmogenic Right Ventricular Dysplasia Program, The Johns Hopkins University School of Medicine, Baltimore, USA

Education and training

1989–1990 Advanced electrophysiology fellow, University of Michigan

1986–1989 Cardiology fellow and electrophysiology fellow, Johns Hopkins

1984–1986 Resident in Medicine, Massachusetts General Hospital

1983–1984 Intern in Medicine, Massachusetts General Hospital

1983 MD, Harvard Medical School, Boston, USA

1979 BA, Department of Chemistry, Williams College, Williamstown MA, Thesis Title: Conformational Studies of Poly-L-Lysine Using the Electron Spin Resonance Technique

Societies (selected)

2007–present Association of University Cardiologists

2007–present American Clinical and Climatological Association

2005–present American Heart Association

1991–present American College of Cardiology (JACC Editorial Board 1994–present; Co-director Board Certification Course 2004–present)

1991–present Heart Rhythm Society (first vice president: 2011–2012)